Novartis has announced that, in a move to consolidate their eye disease research projects in the United States, it will be moving 120 jobs from the company’s Texas base in Forth Worth to Cambridge, Massachusetts. The decision means that the Swiss-based pharmaceutical company will be closing the doors on its Biomedical Research Group, which is based out of Alcon Labs in Fort Worth.
According to Alcon spokesperson Dave Jackson the move means that 120 Texas-based employees will be out of a job come June 11, although employees are reportedly being given the opportunity to apply for jobs at the Cambridge project, which currently employs 1,600 scientists in Massachusetts. According to an article on the PharmaLive website:
Novartis acquired Alcon, a producer of ophthalmic surgical products and pharmaceuticals, in 2011. After the purchase, Novartis said it was expanding its facilities in south Fort Worth with a Finance Service Center for the company’s North American operation as well as integrating its Atlanta-based Ciba Vision and Novartis Ophthalmic units into Alcon’s operations. Alcon now has 4,800 employees…The City Council established a reinvestment zone for Alcon’s campus off Interstate 35W near Interstate 20 and granted an 80 percent tax abatement on the incremental real and personal property taxes for 10 years. Alcon said it planned to spend more than $11 million in that expansion.
Dave Jackson also explained that, for those employees who choose not to apply for jobs in Cambridge, a severance package will be available.